Personalised relaxation practice to improve sleep and functioning in patients with chronic fatigue syndrome and depression: study protocol for a randomised controlled trial.

Autor: Macnamara CL; Department of Human Behaviour (Psychiatry), UNSW, Level 1, 30 Botany Street, Sydney, NSW, 2052, Australia., Cvejic E; Department of Human Behaviour (Psychiatry), UNSW, Level 1, 30 Botany Street, Sydney, NSW, 2052, Australia.; School of Public Health, University of Sydney, Sydney, Australia., Parker GB; Department of Human Behaviour (Psychiatry), UNSW, Level 1, 30 Botany Street, Sydney, NSW, 2052, Australia.; Black Dog Institute, Prince of Wales Hospital, Randwick, Sydney, Australia., Lloyd AR; Viral Immunology Systems Program, The Kirby Institute, University of New South Wales, Sydney, Australia., Lee G; Department of Human Behaviour (Psychiatry), UNSW, Level 1, 30 Botany Street, Sydney, NSW, 2052, Australia., Beilharz JE; Department of Human Behaviour (Psychiatry), UNSW, Level 1, 30 Botany Street, Sydney, NSW, 2052, Australia., Vollmer-Conna U; Department of Human Behaviour (Psychiatry), UNSW, Level 1, 30 Botany Street, Sydney, NSW, 2052, Australia. ute@unsw.edu.au.
Jazyk: angličtina
Zdroj: Trials [Trials] 2018 Jul 11; Vol. 19 (1), pp. 371. Date of Electronic Publication: 2018 Jul 11.
DOI: 10.1186/s13063-018-2763-8
Abstrakt: Background: Chronic fatigue syndrome (CFS) and major depressive disorder (MDD) are both debilitating but heterogeneous conditions sharing core features of fatigue, unrefreshing sleep, and impaired functioning. The aetiology of these conditions is not fully understood, and 'best-practice' treatments are only moderately effective in relieving symptoms. Unrecognised individual differences in the response to such treatments are likely to underlie poor treatment outcomes.
Methods/design: We are undertaking a two-group, parallel, randomised controlled trial (RCT) comparing the effects of a personalised relaxation intervention on sleep quality, daytime symptoms, and functioning in patients with CFS (n = 64) and MDD (n = 64). Following identification of the method that best enhances autonomic responding (such as heart rate variability), participants randomised to the active intervention will practise their recommended method nightly for 4 weeks. All participants will keep a sleep diary and monitor symptoms during the trial period, and they will complete two face-to-face assessments, one at baseline and one at 4 weeks, and a further online assessment to evaluate lasting effects of the intervention at 2 months. Assessments include self-report measures of sleep, wellbeing, and function and monitoring of autonomic responses at rest, in response to the relaxation method and during nocturnal sleep. Treatment outcomes will be analysed using linear mixed modelling.
Discussion: This is the first RCT examining the effects of a personalised relaxation intervention, pre-tested to maximise the autonomic relaxation response, in patients with unrefreshing sleep and fatigue attributed to CFS or MDD. Detailed monitoring of sleep quality and symptoms will enable sensitive detection of improvements in the core symptoms of these debilitating conditions. In addition, repeated monitoring of autonomic functioning can elucidate mechanisms underlying potential benefits. The findings have translational potential, informing novel, personalised symptom management techniques for these conditions, with the potential for better clinical outcomes.
Trial Registration: Australian and New Zealand Clinical Trials Registry (ANZCTR), ACTRN12616001671459 . Registered on 5 December 2016.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje